Page 142 – Channelchek

Comstock Inc. (LODE) – Comstock Fuels Executes its First International License Agreement

Posted on September 19, 2024September 19, 2024 by cpereira@noblefcm.com

Thursday, September 19, 2024

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

International license agreement.Comstock Fuels executed a non-binding term sheet to grant SACL Pte. Limited, a Singapore-based renewable fuel project developer, an exclusive marketing agreement for Comstock Fuels’ advanced lignocellulosic biomass refining processes in Australia and New Zealand. The term sheet includes a master non-exclusive intellectual property license for the sole purpose of developing, financing, constructing, and managing renewable fuels production facilities. SACL has identified initial sites for the construction of three refineries in Australia.

Terms of the agreement. Comstock Fuels will contribute site specific technology rights in exchange for a 20% equity stake in each refinery. Comstock will provide each producer with engineering support in exchange for 3% of each facilities’ capital and construction costs, increasing to 6% at and above a capacity of 250,000 metric tons per year (MTPY), including an upfront payment of $2.5 million payable upon execution of a site license agreement. Comstock Fuels will earn a royalty fee equal to 3% of the total sales of licensed products by each facility, increasing to 6% at and above a capacity of 250,000 metric tons per year.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Fed Lowers Interest Rates by Half Point in First Cut Since 2020

Posted on September 18, 2024September 18, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– The Federal Reserve cuts interest rates by 50 basis points to a range of 4.75%-5.0%.
– Two additional rate cuts are expected later this year, with four more in 2025.
– The decision reflects concerns about a slowing labor market and confidence in inflation returning to target levels.

The Federal Reserve cut interest rates by half a percentage point on Wednesday, marking its first rate reduction since 2020. This shift signals the conclusion of the Fed’s most aggressive inflation-fighting campaign since the 1980s. With this cut, the central bank’s benchmark interest rate now stands at a new range of 4.75%-5.0%, ending the 23-year high range it held since July 2023. The decision was part of the Federal Open Market Committee’s (FOMC) two-day policy meeting.

This rate cut comes amid mounting concerns over the slowing U.S. labor market and the Fed’s renewed confidence in inflation trending downward. Employment data for the summer reflected weaker job growth, with only 118,000 jobs created in June, followed by 89,000 in July and 142,000 in August—well below the monthly average from the previous year. Fed Chair Jerome Powell emphasized the need to support a strong labor market while continuing to work toward stable prices.

Fed officials are now projecting two more 25-basis point cuts before the end of the year, followed by four more cuts in 2025, creating a path for a total of six additional cuts in the coming years. While the decision was not unanimous, with Fed Governor Michelle Bowman preferring a smaller 25-basis point cut, the majority consensus agreed on a more aggressive approach.

Inflation, which had surged following the pandemic, has shown signs of cooling in recent months. The Consumer Price Index (CPI) has consistently reported progress, with inflation now nearing the Fed’s long-term target of 2%. This, combined with the weaker labor market, has given the Fed confidence to make this significant cut.

Jerome Powell’s comments at Jackson Hole in August hinted at the possibility of such a move. He stressed that the Fed would do everything possible to support a strong labor market and indicated that the central bank had the flexibility to lower rates further if needed. Wednesday’s decision reflects the Fed’s focus on both inflation and employment as key factors influencing future monetary policy.

Despite the easing of inflation, the Fed has remained cautious, signaling that while they expect inflation to continue its downward trend, they are still closely monitoring economic data. Officials also updated projections, predicting an uptick in the unemployment rate to 4.4% and stable economic growth of 2% for the next two years.

As investors and businesses adjust to the new monetary landscape, the Fed’s rate cut is expected to influence borrowing costs, stock market activity, and broader economic behavior. The next steps, as outlined by the central bank, will depend heavily on incoming data related to inflation and employment.

MustGrow Biologics Corp. (MGROF) – A New Opportunity

Posted on September 18, 2024September 18, 2024 by cpereira@noblefcm.com

Wednesday, September 18, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Funding. MustGrow announced yesterday that the Company is receiving funding from Agriculture and Agri-Food Canada (AAFC) to investigate its mustard-derived ingredient. The ingredient could potentially be used in human and animal health and food applications. The funding amount was not disclosed. The Company will continue to focus on its core business outside of the program, with the anticipation of more state approvals for TerraSante, in our view.

The Program. Under the program, the Company and AAFC will look at bioactive components in mustard seed and assess yellow mustard extracts for potential antibiotic and gut health applications in both humans and animals. They will also test the selected bioactive components for antifungal and antibacterial activities against food spoilage microbes and disease pathogens and for use as ingredients in functional foods and nutraceuticals for improved immunity and gut health in both humans and animals.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Fed Poised for First Rate Cut in Four Years as Market Speculates on Scale

Posted on September 18, 2024September 18, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– Investors expect the Fed to cut rates for the first time in four years.
– A 50 basis point cut is increasingly seen as possible, but a 25 basis point cut is more likely.
– The Fed will also provide guidance on future rate cuts and the economic outlook.

The Federal Reserve is set to cut interest rates for the first time in four years, marking a pivotal moment in its monetary policy approach. Investors and market analysts are divided on the expected size of the cut. Recent market moves suggest a growing possibility of a 50 basis point reduction, though a more conservative 25 basis point cut seems more likely, according to comments from several Federal Reserve officials.

The cut, which will bring the Federal Funds rate down to a range of 5.0% to 5.25%, represents a shift from the Fed’s aggressive inflation-fighting stance. The central bank has been steadily raising rates since 2022 to combat rising prices, but as inflation has started to slow, the Fed has turned its attention toward stabilizing the labor market and supporting economic growth.

According to Wilmington Trust bond trader Wilmer Stith, a 50 basis point cut, while a possibility, is still uncertain. He noted that a more moderate 25 basis point reduction might be the more palatable option for the Fed’s policy committee.

Recent economic data, including cooling inflation numbers, have spurred calls for a larger cut. However, the Fed remains cautious, emphasizing that it will continue to monitor the labor market and broader economic trends to determine the best course of action for future cuts.

Chief economist Michael Feroli from JPMorgan has called for a more aggressive 50 basis point cut, arguing that the shift in risks justifies a bolder move. He believes that the central bank needs to recalibrate its policy to maintain economic stability. Conversely, former Kansas City Fed president Esther George expects a more modest quarter-point cut, noting that the Fed might use this opportunity to signal the potential for deeper cuts later in the year.

Fed Chair Jerome Powell has emphasized the importance of sustaining a strong labor market, pledging to do everything possible to avoid further deterioration. He has expressed concern over economic weakening and stressed that the Fed has sufficient room to cut rates if needed to support the economy. However, Powell also acknowledged that inflationary pressures have started to ease, and that gives the central bank flexibility.

The Federal Open Market Committee (FOMC) will also release updated projections for unemployment, inflation, and economic growth alongside the rate decision. These forecasts, particularly the “dot plot” outlining future rate expectations, will provide important guidance on the central bank’s approach to monetary policy through the end of the year and into 2025.

Investors will be watching closely, with the potential for deeper cuts likely to influence market sentiment. Powell’s press conference following the rate decision is expected to shed light on the Fed’s next moves, offering insights into how aggressively the central bank will act to safeguard the economy from potential recession risks.

Trump Family Unveils Crypto Project Details: Who Can Buy World Liberty Financial Tokens?

Posted on September 18, 2024September 18, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– 63% of World Liberty Financial tokens will be available to the public.
– The platform will offer decentralized finance services like lending and investing.
– Concerns arise over the project’s viability amid the Trump family’s limited crypto experience.

The Trump family has finally revealed key details about their latest venture in the digital currency space: World Liberty Financial, a crypto project designed to reshape how people interact with decentralized finance (DeFi). At an event held on X (formerly Twitter), the team behind the project disclosed who can buy the platform’s tokens and how those tokens will be allocated, offering greater transparency on a project that has generated significant interest over the past few weeks.

Token Distribution and Public Availability

According to founder Zak Folkman, 63% of the total tokens from World Liberty Financial (WLFI) will be made available for public purchase, while 20% will be reserved for the founding team, which includes members of the Trump family. An additional 17% will be set aside for user rewards, meant to incentivize active participation on the platform. Folkman assured listeners that there will be no pre-sales or early access for insiders, aiming to keep the token launch fair and accessible to all potential investors.

This announcement has garnered attention due to earlier leaked reports that suggested a 70% founder allocation, which raised concerns about the transparency and fairness of the project. The revised structure has slightly alleviated some of those concerns, although skepticism remains about whether the Trump family can successfully navigate the complex and volatile cryptocurrency market.

Trump’s Shift Toward Crypto

During the event, Donald Trump took center stage, offering insights into his evolving stance on cryptocurrency. Initially, the former president admitted he had little interest in digital currencies, but his involvement grew after witnessing the success of his own NFT collections. These collections, sold to supporters and collectors, were paid for using cryptocurrency, which he said helped change his perception of the digital finance world.

Trump remarked, “Crypto is something we have to do, whether we like it or not.” He also criticized the Securities and Exchange Commission (SEC) for what he perceives as an overly aggressive stance toward the industry. This sentiment reflects ongoing frustration among crypto entrepreneurs, many of whom feel that the SEC has stifled innovation through a regulatory approach focused on enforcement rather than clear guidelines.

Lofty Goals for World Liberty Financial

The Trump family and their business partner, Steve Witkoff, are aiming to create more than just a cryptocurrency token. They envision World Liberty Financial as a comprehensive DeFi platform, offering services that would allow users to borrow, lend, and invest in digital assets. Witkoff, who has traditionally worked in real estate, spoke about his excitement in helping to build a platform focused on “frictionless finance,” designed to provide opportunities for individuals who have limited access to traditional credit or banking services.

Despite these ambitious goals, the project has faced criticism and skepticism, with questions arising about the Trumps’ limited experience in the cryptocurrency sector. While the Trump brand brings name recognition, the complex nature of blockchain technology and DeFi operations may pose challenges for the team as they seek to gain credibility in the space.

Potential Risks and Challenges

Launching this crypto platform during a heated presidential campaign adds further intrigue. Trump’s increasing support for cryptocurrency on the campaign trail could appeal to a niche group of crypto-friendly voters, but it also raises the stakes for this project. Should World Liberty Financial stumble, it could tarnish Trump’s image among both supporters and investors.

Moreover, the cryptocurrency market is notoriously volatile, and new projects like World Liberty Financial often face significant obstacles to achieving long-term success. Investors and enthusiasts will be closely watching how this project unfolds, particularly given the Trumps’ high-profile involvement.

Moving Forward

The team behind World Liberty Financial has promised to release more updates on the project’s progress via official social media channels in the coming months. Meanwhile, potential investors have been urged to stay alert to possible scams, as the project has already attracted significant public interest.

As the Trump family forges ahead in the world of crypto, many remain curious—and cautious—about whether World Liberty Financial can live up to its promises or whether it will become another footnote in the rapidly evolving cryptocurrency landscape.

Organon to Acquire Dermavant, Expanding into U.S. Dermatology with VTAMA Cream

Posted on September 18, 2024September 18, 2024 by slightbourne@noblecapitalmarkets.com

Organon, a global healthcare company focused on improving women’s health, announced a major acquisition of Dermavant Sciences Ltd., a subsidiary of Roivant. This acquisition includes Dermavant’s innovative dermatologic therapy, VTAMA® (tapinarof) cream, 1%, which is approved for treating plaque psoriasis and is currently under FDA review for atopic dermatitis.

The acquisition enhances Organon’s presence in the U.S. dermatology market, adding to their international portfolio. This move aligns with Organon’s mission to provide treatments for conditions that disproportionately affect women. The inclusion of VTAMA cream, which addresses psoriasis and potentially atopic dermatitis, fits into their strategic goal of expanding access to effective therapies. Dermavant’s established commercial team will integrate with Organon’s market capabilities, further extending the product’s reach.

Dermavant’s VTAMA cream has been a game changer in the dermatology space. Approved in May 2022, it provides a non-steroidal, once-daily treatment option for plaque psoriasis, a condition that impacts over 8 million Americans. Unlike traditional steroid treatments, VTAMA cream is free of safety warnings, making it an appealing option for long-term use. The product is also under review to extend its use to treat atopic dermatitis, a common inflammatory skin condition affecting over 16.5 million adults and 9.6 million children in the U.S.

Organon’s acquisition of Dermavant not only strengthens its foothold in the U.S. market but also provides a new channel for global growth. Organon CEO Kevin Ali emphasized that this acquisition is part of their commitment to improving women’s health and that integrating Dermavant’s operations would accelerate VTAMA’s availability to patients. With Organon’s commercial scale, they expect to significantly increase patient access to this novel therapy globally.

The acquisition is structured with an upfront payment of $175 million, a milestone payment of $75 million contingent upon FDA approval for atopic dermatitis, and additional payments of up to $950 million tied to commercial milestones. Dermavant shareholders will also receive tiered royalties on net sales. The deal, subject to regulatory approvals, is expected to close by the fourth quarter of 2024.

The acquisition complements Organon’s portfolio of women’s health solutions, biosimilars, and established medicines, bringing a much-needed dermatological therapy into its fold. VTAMA cream has been a success, becoming the top branded topical for plaque psoriasis within just two months of its launch. Organon expects that the therapy will continue to grow, especially as the FDA considers its use for atopic dermatitis.

For Dermavant, the deal provides an opportunity for continued growth, with the support and scale of Organon to take VTAMA to new markets and potentially reach millions of patients globally.

With this acquisition, Organon is well-positioned to further expand its impact in dermatology, providing innovative treatments for plaque psoriasis and potentially atopic dermatitis. The company continues to focus on improving the lives of patients, particularly women, by offering accessible and effective healthcare solutions.

Release – Air Force Awards Kratos Sole Source $79.8 Million Contract for 60 BQM-167A Target Aircraft Systems (Lot 20)

Posted on September 17, 2024September 17, 2024 by dburczyk@noblecapitalmarkets.com

Research News and Market Data on KTOS

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, today announced that Kratos has received a $79,870,161.48 Firm Fixed Price delivery order for the Lot 20 procurement of 60 aircraft, mission kits, certain flight consumables, and technical data for the BQM-167A Air Force Subscale Aerial Target (AFSAT) under a five-year base contract. The award incorporates Gas, Aero, Payload, Power (GAPP) enhancements that include the largest capability upgrade to date for the BQM-167A Product Baseline. The increased capabilities provided by the GAPP upgrade marks an indisputable enhancement in the BQM-167A’s evolution to keep pace replicating more advanced threats, thereby improving the weapon systems verification and training efforts the BQM-167A helps enable for the USAF. This contract also represents the largest single buy of BQM-167As by the Air Force Life Cycle Management Center, Eglin AFB, Florida.

Kratos / USAF BQM-167A AFSAT in Flight with Extremal Mission Payloads

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3fa3de68-7494-4fbd-83d1-506c8ca9333c

Steve Fendley, President of Kratos Unmanned Systems Division, said, “As our nation’s peer threat countries continuously grow their capabilities in both technology and mass, our country must train our military and test our defenses against current, relevant, accurate, and representative threat systems. Kratos is proud its BQM-167A has been a part of this solution for over 20 years and of the GAPP upgrades which increase the capability and extend the relevance of this affordable threat representative aircraft for years to come. We appreciate the collaborative, cooperative, positive team relationship we share with the USAF which enables Kratos and the USAF’s personnel to work in concert to realize these critical capability systems for our nation’s defense.”

Work will be performed at a Kratos manufacturing facility. Total contract value if the options for Lots 17-21 and Spares are all exercised at the maximum production quantities is $374,043,801.76.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 31, 2023, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Burghoff
claire.burghoff@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Release – MustGrow Receiving Funding from Agriculture and Agri-Food Canada for Human & Animal Health Applications

Posted on September 17, 2024September 17, 2024 by dburczyk@noblecapitalmarkets.com

Research News and Market Data on MGROF

MustGrow will be receiving funding from Agriculture and Agri-Food Canada to investigate mustard-derived ingredient opportunities in human & animal health applications.
Potential product opportunities may include application in functional foods and nutraceuticals for improved immunity and gut health in humans, as natural food preservatives, as well as a replacement for antibiotics in animal feeds.

SASKATOON, Saskatchewan, Canada, September 17, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“) is pleased to announce funding from Agriculture and Agri-Food Canada (“AAFC“) to investigate mustard-derived ingredient opportunities in human & animal health and food applications (the “Project“). The funding is provided through the AgriScience Program – Projects Component, under the Sustainable Canadian Agricultural Partnership.

The work will be conducted in connection with AAFC’s Guelph Research & Development Centre (“GRDC“) located in Guelph, Ontario, Canada, and it will be led by Dr. Rong Cao. Costs associated with the Project will be covered by both MustGrow and AAFC through a Collaborative Research and Development Agreement under the AgriScience Program. All investigational research activities will be conducted at the GRDC. The funding amount received from AAFC is subject to the negotiation of the Collaborative Research and Development Agreement. The funding does not imply Government of Canada endorsement of MustGrow’s findings, products, or practices.

MustGrow has always suspected potential product ingredient opportunities of mustard derivatives in human & animal health applications, including functional foods and nutraceuticals for improved immunity and gut health in humans, as natural food preservatives, as well as a replacement for antibiotics in animal feeds. The GRDC is a leading research institute in food health attributes and safety.

MustGrow will continue to focus on its core business in natural agricultural biopesticides, biofumigants, and biofertility products derived from the mustard seed or its processing by-products, while pursuing this opportunity in human and animal health in a cost-effective and expedient structure. MustGrow’s biofertility product, TerraSante^TM, is currently being marketed and sold in the United States, with additional biocontrol development programs underway with four global partners: Bayer, Sumitomo Corporation, Janssen PMP, and NexusBioAg.

The Health Program

Together, MustGrow and AAFC will:

Analyze the major bioactive components in mustard seed that may have antibiotic and gut health applications in both humans and animals.
Assess yellow mustard extracts for efficacy in converting glucosinolates into active ingredients that may have antibiotic and gut health applications in both humans and animals.
Test the selected bioactive components for antifungal and antibacterial activities against food spoilage microbes and disease pathogens, including the banana-plaguing disease Fusarium wilt TR4.
Test the selected bioactive components for antioxidant and anti-inflammatory effects, for use as ingredients in functional foods and nutraceuticals for improved immunity and gut health in both humans and animals.

MustGrow has always believed that there is a potential for new products to be developed and deployed in antibiotic and gut health applications using bioactives derived from the mustard seed. These new applications would be directed at antimicrobial, antioxidant, and anti-inflammatory uses in functional foods, gut health, and nutraceuticals in both human and animal health.

Global Threat

Antimicrobial resistance (“AMR“) has become a leading global cause of death and is one of the greatest global health challenges: a growing threat to both human and animal health, as well as global food security.⁽¹⁾ In 2019, an estimated 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths directly attributable to bacterial AMR itself.⁽²⁾

The 2022 global animal antibiotics market was valued at US$5.6 billion, with usage estimates for cattle, sheep, chicken, and pigs expected to increase to 107,472 tonnes by 2030 (an 8% increase over 2020).⁽³⁾⁽⁴⁾Experts warn that overuse of antibiotics in livestock could lead to potentially fatal antibiotic-resistant infections in these animals, and alarmingly in humans as well, as new bacteria emerge with built-in resistance to the human immune system.⁽⁴⁾

Some estimate antibiotic-resistant infections will kill as many as 10 million per year people by 2050 – on par with the 2020 global death toll from all cancers.⁽⁵⁾

Sources:

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East. Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California. Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features. MustGrow has approximately 51.6 million basic common shares issued and outstanding and 55.7 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson

Director & CEO

Phone: +1-306-668-2652

info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the product ingredient opportunities of mustard derivatives in human & animal health application, the use of the proceeds of the funding; the outcome of the Health Program; the continued persistence of antimicrobial resistance; and the Company’s focus on its core products and business. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. These risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Disclaimer:

This news release may include references to third-party information, opinions, or statements. The Company does not guarantee the accuracy, reliability, or completeness of any information provided by third parties. Such information is included solely for informational purposes and should not be construed as endorsements or representations. Readers are advised to independently verify any claims, statements, or conclusions drawn from third-party sources before making any decisions or taking action based on this information.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2024 MustGrow Biologics Corp. All rights reserved.

Thor Explorations Expands into Côte d’Ivoire with Guitry Gold Project Acquisition

Posted on September 17, 2024September 17, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– Thor acquires Guitry Gold Project from Endeavour Mining, expanding its reach in West Africa.
– The acquisition strengthens Thor’s position in Côte d’Ivoire’s gold-rich Birimian Greenstone Belt.
– Thor aims to further develop Guitry and Boundiali projects for gold exploration and production.

Thor Explorations Ltd. has made a significant strategic move by expanding into Côte d’Ivoire with the acquisition of the Guitry Gold Exploration Project from Endeavour Mining Corporation. This acquisition marks Thor’s latest effort to strengthen its gold exploration operations in the highly prospective West African region. The deal is valued at $100,000 plus a 2% net smelter royalty, with Thor acquiring a 100% interest in the project. Pending final approvals, including from the Minister of Mines, Thor is set to make its mark in one of the continent’s most promising gold regions.

Côte d’Ivoire, a West African nation known for its mineral-rich Birimian Greenstone Belt, hosts a considerable portion of the region’s gold reserves. The Guitry Gold Project, located approximately 220 kilometers west of the capital, Abidjan, covers 295 square kilometers of land that contains valuable geological formations. According to Thor Explorations, the Guitry Project has already yielded several high-grade gold drill intersections, showing potential for substantial future discoveries.

In addition to the Guitry Project, Thor has also secured an option agreement to earn up to an 80% interest in the Boundiali Exploration Permit. This early-stage permit, located in the highly prospective Boundiali Greenstone Belt in northwestern Côte d’Ivoire, contains large soil geochemical anomalies that have yet to be fully explored. Thor plans to carry out a comprehensive exploration program over the next 36 months and aims to leverage these opportunities to further strengthen its presence in the region.

Segun Lawson, Thor’s President and CEO, expressed enthusiasm for the company’s expansion into Côte d’Ivoire. Lawson emphasized that the country is an emerging leader in gold exploration, hosting over 30% of West Africa’s greenstone belts. He highlighted the significance of Guitry’s advanced exploration status, with its gold-in-soil geochemical anomalies offering strong indications of significant resource potential. Thor’s exploration team has already identified two key prospects, Krakouadiokro and Gbaloukro, where additional drilling is planned to uncover more gold deposits.

Thor’s acquisition of the Guitry Project presents numerous growth opportunities, not only in terms of resource discovery but also in the company’s ability to implement sustainable mining practices. The company is targeting a maiden gold resource estimate of between 500,000 and 1,000,000 ounces by the end of 2025. Lawson further mentioned that Thor plans to continue its exploration activities in Côte d’Ivoire, building upon its successful track record in West Africa.

By expanding into Côte d’Ivoire, Thor Explorations is poised to unlock significant value from the region’s rich geological formations. The acquisition of Guitry and the Boundiali exploration permit fits into Thor’s long-term strategy of increasing its gold production and leveraging its expertise in exploration. Investors and stakeholders are optimistic that these assets will contribute to Thor’s growth and profitability in the coming years.

Vince Holding Corp. (VNCE) – Positioning For a Favorable 2025

Posted on September 17, 2024September 17, 2024 by cpereira@noblefcm.com

Tuesday, September 17, 2024

500 5th Avenue 20th Floor New York, NY 10110 United States Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 599 Key Executives Name Title Pay Exercised Year Born Mr. Jonathan CEO & Director 825.62k N/A 1958 Ms. Marie Fogel Senior VP and Chief Merchandising & Manufacturing Officer 633.19k N/A 1961 Mr. John Chief Financial Officer

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fiscal Q2 overachieves expectations. Q2 revenues of $74.2 million were much better than our $68.5 million estimate and supported a “beat” in our adj. EBITDA estimate, a positive $2.4 million versus our adj. EBITDA loss estimate of $1.5 million. The largest portion of the variance was due to timing of wholesale order shipments, which pushed into the second quarter. We estimate that those revenues were roughly $5 million.

Profit margins improved, outlook appears favorable. Gross profit margins increased 80 basis points from year earlier levels, as the company shifts away from price promotions and with a focus on tight cost controls. management guided for operating margins to increase 350 to 450 basis points for the full year, bolstered by a shift away from discounting, higher pricing, and lower freight costs.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

PDS Biotechnology (PDSB) – PDS Presents Phase 2 Data Update At ESMO Conference

Posted on September 17, 2024September 17, 2024 by cpereira@noblefcm.com

Tuesday, September 17, 2024

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional Clinical Details Presented At ESMO Conference. PDS Biotech presented an update to its Phase 2 VERSATILE-002 trial at the European Society for Medical Oncology (ESMO), adding detail to the data announced in June 2024. We see these Phase 2 data as highly encouraging for the Phase 3 VERSATILE-003 trial testing the doublet combination and the triplet combination (Versamune HPV with PDS01ADC and Keytruda) against Keytruda alone.

Trial Continues As Patient Survival Continues To Surpass Other Treatments. The VERSATILE-002 enrolled 53 patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). As of the May 17, 2024, analysis date, 27 patients remain alive with some reaching the 3-year survival point. Out of those alive, 10 remain on treatment and 17 are followed for survival.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Kratos Defense & Security (KTOS) – Raising Price Target

Posted on September 17, 2024September 17, 2024 by cpereira@noblefcm.com

Tuesday, September 17, 2024

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Raising Price Target. With KTOS shares hitting our prior $22 price target, we are raising our price target to $26. We are maintaining our Outperform rating on the shares. We view the recent awards and demonstrations as further confirmation of the Kratos strategy in providing leading edge disruptive technology products and systems.

CR Concern. Although we remain confident in the long-term success of the Company, the potential for another extended Continuing Resolution remains a concern in the near-term. The Federal government’s fiscal year ends September 30th and we do not expect a 2025 budget to be passed before then. The concern is for an extended CR, like we had in fiscal 2024, which pushes new awards and contracts to the right.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

US Dollar Sinks to One-Year Low Against Yen Amid Growing Speculation of Aggressive Fed Rate Cut

Posted on September 17, 2024September 17, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– The U.S. dollar hits its lowest level in over a year against the yen, driven by expectations of a larger-than-expected Fed rate cut.
– Market pricing now reflects a 61% chance of a 50-basis-point cut at this week’s Federal Reserve meeting.
– This volatility comes as other central banks, like the Bank of Japan and Bank of England, are expected to hold rates, creating a global divergence in monetary policy.

The U.S. dollar has plummeted to its lowest level in over a year against the Japanese yen, fueled by growing market speculation that the Federal Reserve may adopt a more aggressive approach to rate cuts. Following reports from The Wall Street Journal and Financial Times, traders are increasingly betting on a 50-basis-point (bp) cut during the Fed’s policy meeting this week, up from the previously anticipated 25-bp cut. This shift has caused ripples across the currency and bond markets, with investors closely monitoring the broader impact on global markets and the U.S. economy.

The U.S. Federal Reserve’s monetary policy decisions have far-reaching effects, not only on domestic markets but also on global financial stability. As the central bank weighs its options, the potential for a larger-than-expected rate cut is being driven by concerns about weakening inflation data and slowing economic growth. Last week’s softer Consumer Price Index (CPI) numbers added to the narrative that the Fed might be willing to move more aggressively to support the economy, despite earlier hawkish signals.

As expectations for a 50-bp cut grow, the U.S. dollar has seen a sharp decline against key currencies, including the Japanese yen. The dollar fell as low as 139.58 yen during Monday’s Asian trading hours, marking the lowest point since July 2023. This drop reflects the mounting concern that the dollar will weaken further if the Fed makes an aggressive cut, narrowing the interest rate gap between the U.S. and other countries like Japan, which has kept its rates low for an extended period.

Currency markets have been particularly sensitive to central bank actions, and the U.S. dollar’s recent dip is a prime example of this. The divergence in monetary policies between the Federal Reserve, the Bank of Japan (BOJ), and the Bank of England (BoE) has created a complex dynamic. While the Fed is now considering rate cuts to stimulate the economy, the BOJ is expected to hold rates steady at 0.25% at its policy meeting later this week. Meanwhile, the Bank of England is also expected to keep its key rate at 5% after initiating a small rate cut in August.

This growing disparity in interest rates is driving the yen higher, as investors unwind yen-funded carry trades—investments made by borrowing in yen to purchase higher-yielding foreign assets. The narrowing interest rate gap between Japan and the U.S. has caused these trades to lose their appeal, pushing the yen higher and the dollar lower. The broader foreign exchange (FX) market has also seen major currencies like the euro and the British pound rise against the dollar, signaling global uncertainty about the U.S. economic outlook.

The potential for a 50-bp Fed rate cut presents both opportunities and risks for investors. On one hand, lower interest rates could spur economic activity by making borrowing cheaper and encouraging investment. This could provide a boost to stock markets, particularly in sectors like technology and consumer goods, which tend to benefit from looser monetary policy.

On the other hand, a weaker dollar could create challenges for U.S. companies with significant international operations. As the dollar falls, the cost of imported goods rises, leading to potential inflationary pressures. Additionally, for companies that generate significant revenue abroad, a weaker dollar could erode profit margins when converting foreign earnings back into U.S. dollars.

As the Federal Reserve’s September meeting approaches, all eyes will be on how policymakers navigate this delicate balance. A 50-bp cut, if it happens, would represent a significant shift from the Fed’s earlier signals of a more gradual approach to rate reductions. Traders are pricing in a 61% chance of this larger cut, compared to just 15% last week, highlighting the rapid change in market expectations.

Meanwhile, the global financial system will continue to adjust to the diverging monetary policies of major central banks. Investors, particularly those involved in currency trading or holding international assets, will need to remain vigilant as the Fed’s decision could prompt further volatility across markets.

In the near term, the U.S. dollar’s performance against major currencies will serve as a key indicator of investor sentiment. If the Fed opts for a less aggressive cut, the dollar could regain some strength. However, if the central bank signals a prolonged period of rate cuts, the dollar’s weakness may persist, especially against currencies like the yen and the euro, which are being supported by their respective central banks’ policies.